Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital
- PMID: 11233850
- DOI: 10.1080/003655401750065544
Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital
Abstract
The characteristics of candidemia before and after the introduction of fluconazole were compared at our institution. In the pre-fluconazole era (1986-89), the incidence of candidemia rose from 0.02% to 13% over the course of 4 y. Candida albicans accounted for 44/66 isolates (67%) and C. glabrata and C. parapsilosis were the predominant non-albicans species (9% each). In one-third of cases antifungal therapy was not given and the overall mortality rate was 55%. During the fluconazole era (1994-97), the incidence of candidemia remained constant between 1994 and 1996 at 0.09-0.11% and dropped to 0.06% in 1997. Bloodstream infection associated with neutropenia increased significantly but only accounted for 13% of cases; antifungal prophylaxis was not employed. The isolation of C. albicans decreased (n = 49; 50%) whereas isolation of both C. parapsilosis (n = 23; 24%) and C. tropicalis (n = 16; 16%) increased. The vast majority of patients received antifungal therapy and the overall mortality rate was 39%. These findings show that the incidence of candidemia rose steadily prior to the fluconazole era and then stabilized in spite of a shift towards non-albicans species. When candidemia was encountered in the fluconazole era, it was rare not to give antifungal treatment.
Similar articles
-
Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007.BMC Infect Dis. 2010 Oct 28;10:312. doi: 10.1186/1471-2334-10-312. BMC Infect Dis. 2010. PMID: 21029444 Free PMC article.
-
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.Clin Infect Dis. 2009 Jun 15;48(12):1695-703. doi: 10.1086/599039. Clin Infect Dis. 2009. PMID: 19441981
-
Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital.Medicine (Baltimore). 2002 Nov;81(6):425-33. doi: 10.1097/00005792-200211000-00003. Medicine (Baltimore). 2002. PMID: 12441899
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Epidemiology and treatment of hematogenous candidiasis: a Brazilian perspective.Braz J Infect Dis. 2000 Jun;4(3):113-8. Braz J Infect Dis. 2000. PMID: 10934493 Review.
Cited by
-
The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.Infect Immun. 2005 Sep;73(9):6191-3. doi: 10.1128/IAI.73.9.6191-6193.2005. Infect Immun. 2005. PMID: 16113347 Free PMC article.
-
Fecal fungal flora of pediatric healthy volunteers and immunosuppressed patients.Mycopathologia. 2005 Jun;159(4):515-20. doi: 10.1007/s11046-005-3451-2. Mycopathologia. 2005. PMID: 15983737
-
Continuing Shifts in Epidemiology and Antifungal Susceptibility Highlight the Need for Improved Disease Management of Invasive Candidiasis.Microorganisms. 2022 Jun 13;10(6):1208. doi: 10.3390/microorganisms10061208. Microorganisms. 2022. PMID: 35744725 Free PMC article. Review.
-
Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.Antimicrob Agents Chemother. 2009 Feb;53(2):609-14. doi: 10.1128/AAC.00769-08. Epub 2008 Nov 17. Antimicrob Agents Chemother. 2009. PMID: 19015329 Free PMC article. Clinical Trial.
-
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.J Clin Microbiol. 2003 May;41(5):2176-9. doi: 10.1128/JCM.41.5.2176-2179.2003. J Clin Microbiol. 2003. PMID: 12734273 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical